摘要Objective:To characterize the pediatric population with cutaneous leishmaniasis treated at a research center and to determine the therapeutic response and safety of the treatment.Methods:A cross-sectional study was designed,in which data related to sociodemographic information,history of leishmaniasis,clinical characteristics,treatment,therapeutic response and adverse events were collected from the review of the clinical records.Results:The analysis was conducted in 156 pediatric patients with median age of 10.5(6-14)years.Regarding clinical and therapeutic characteristics,the lesions in these patients were mostly single ulcers,primarily located on the upper and lower extremities.A total of 114 patients were managed at Programa de Estudio y Control de Enfer-medades Tropicales(PECET),and 26 of them received more than one treatment.Upon administration of the first therapeutic option,intralesional meglumine antimoniate had a cure rate of 43.18%(19/44 patients),followed by systemic meglumine antimoniate with a cure rate of 40%(8/20)and topical investigational medication with a cure rate of 25%(5/20).The most frequent adverse events were:arthralgia and myalgia for systemic meglumine antimoniate;nausea and vomiting for miltefosine;and local pain,edema,erythema and rash for topical treatment.Conclusions:Although more prospective studies are needed to generate evidence-based recommendations and management protocols,miltefosine appears to be a favorable,safe and well-tolerated therapeutic option for the pediatric population.Despite the high percentage of loss to follow-up,the success achieved in pediatric patients with local treatments suggests that local therapies could also be considered for managing this condition in this population.